PBM Stock Overview
Engages in the development of botanical psilocybin-based psychedelic medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Psyence Biomedical Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.22 |
| 52 Week High | US$699.19 |
| 52 Week Low | US$2.92 |
| Beta | -0.11 |
| 1 Month Change | 25.68% |
| 3 Month Change | -47.18% |
| 1 Year Change | -98.81% |
| 3 Year Change | -99.91% |
| 5 Year Change | n/a |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| PBM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.1% | 2.6% | 1.2% |
| 1Y | -98.8% | -9.1% | 12.5% |
Return vs Industry: PBM underperformed the US Biotechs industry which returned -9.6% over the past year.
Return vs Market: PBM underperformed the US Market which returned 11.5% over the past year.
Price Volatility
| PBM volatility | |
|---|---|
| PBM Average Weekly Movement | 20.6% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: PBM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PBM's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Neil Maresky | www.psyencebiomed.com |
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.
Psyence Biomedical Ltd. Fundamentals Summary
| PBM fundamental statistics | |
|---|---|
| Market cap | US$2.63m |
| Earnings (TTM) | -US$46.59m |
| Revenue (TTM) | n/a |
Is PBM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$46.59m |
| Earnings | -US$46.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -79.88 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -103.7% |
How did PBM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 09:44 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Psyence Biomedical Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.